Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US.
Rajagopalan, Krithika
Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US. [electronic resource] - International journal of chronic obstructive pulmonary disease - 3867-3877 p. digital
Publication Type: Comparative Study; Journal Article
1178-2005
10.2147/COPD.S177097 doi
Administration, Inhalation
Adrenergic beta-2 Receptor Agonists--administration & dosage
Bronchodilator Agents--administration & dosage
Cost-Benefit Analysis
Drug Administration Schedule
Drug Combinations
Drug Costs
Forced Expiratory Volume
Glycopyrrolate--administration & dosage
Humans
Indans--administration & dosage
Lung--drug effects
Markov Chains
Models, Economic
Muscarinic Antagonists--administration & dosage
Nebulizers and Vaporizers--economics
Powders
Pulmonary Disease, Chronic Obstructive--diagnosis
Quinolones--administration & dosage
Randomized Controlled Trials as Topic
Severity of Illness Index
Time Factors
Treatment Outcome
United States
Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US. [electronic resource] - International journal of chronic obstructive pulmonary disease - 3867-3877 p. digital
Publication Type: Comparative Study; Journal Article
1178-2005
10.2147/COPD.S177097 doi
Administration, Inhalation
Adrenergic beta-2 Receptor Agonists--administration & dosage
Bronchodilator Agents--administration & dosage
Cost-Benefit Analysis
Drug Administration Schedule
Drug Combinations
Drug Costs
Forced Expiratory Volume
Glycopyrrolate--administration & dosage
Humans
Indans--administration & dosage
Lung--drug effects
Markov Chains
Models, Economic
Muscarinic Antagonists--administration & dosage
Nebulizers and Vaporizers--economics
Powders
Pulmonary Disease, Chronic Obstructive--diagnosis
Quinolones--administration & dosage
Randomized Controlled Trials as Topic
Severity of Illness Index
Time Factors
Treatment Outcome
United States